Replies to post #236686 on Biotech Values

[vinmantoo]

From that ENTA link

SARS-CoV-2

Enanta is working to discover direct-acting antiviral drug candidates for patients infected with the novel coronavirus, SARS-CoV-2, using a combination of drug target screening and drug design. The company is focused on polymerase and protease inhibitors and is currently optimizing potent lead molecules.

Sounds like progress is being made. Knowing ENTA's skills, this could be very interesting.

[DewDiligence]

I expected some board discussion of EDP-721—ENTA’s newly announced oral RNA destabilizer for HBV. Comments?